Cantrell Susan A
1 DIA, Washington, DC, USA.
Ther Innov Regul Sci. 2016 May;50(3):266-269. doi: 10.1177/2168479015620833.
The term compounding generally refers to the practice of combining, mixing, or altering ingredients of a drug product to create a medication tailored to the needs of an individual patient. Compounding has long been a common activity within the practice of pharmacy. The scope of pharmacy compounding includes the compounding of sterile products, a practice that is especially prevalent within hospitals, home infusion pharmacies, and, more recently, outsourced compounding facilities. Reports of patient morbidity and mortality associated with compounded products have led many over the years, including the US Food and Drug Administration (FDA), to call for more stringent federal oversight of pharmacy compounding to ensure patient safety. A tipping point was reached in 2012 with the emergence of a multistate outbreak of fungal meningitis and other infections in patients who received contaminated steroid injections compounded by the New England Compounding Center in Framingham, Massachusetts. This article describes the history of the practice and regulation of pharmacy compounding, culminating in the passage by Congress of the Compounding Quality Act of 2014.
“调配”一词通常指的是将药品的成分进行组合、混合或改变,以制造出适合个体患者需求的药物。长期以来,调配一直是药学实践中的常见活动。药学调配的范围包括无菌产品的调配,这种做法在医院、家庭输液药房以及最近的外包调配机构中尤为普遍。多年来,包括美国食品药品监督管理局(FDA)在内,与调配产品相关的患者发病和死亡报告促使许多人呼吁对药学调配进行更严格的联邦监管,以确保患者安全。2012年,马萨诸塞州弗雷明汉的新英格兰调配中心调配的受污染类固醇注射剂导致多州爆发真菌性脑膜炎和其他感染,这成为了一个转折点。本文介绍了药学调配实践和监管的历史,最终以国会通过2014年《调配质量法案》告终。